Floatz logo

FES F-18

Stage IV Breast Cancer AJCC v6 and v7

University of WashingtonSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

890 Active assets in the Stage IV Breast Cancer AJCC v6 and v7 cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Loratadine
Noha Mansour
Phase 2BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

FES F-18 is also rated in:

breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
invasive lobular breast carcinomaDormant
B
Indicative ·
56 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →